Form D · Other Technology
Eugene Health, Inc.
New York, NY · CIK 0002031372
Offering snapshot reported Jul 25, 2024 · SEC filing
- Reported sold
- $5.25M Offering amount: $21.3M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 25, 2024 | Initial | $5,250,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519732
Source: Form D, filed Jul 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Beck | Director |
| Jonathan Collins | Director, Executive |
| Word Peake | Director |
| Sam Toole | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
C/O Eugene Health, Inc. 386 Park Ave S. 14 Th Floor
New York, NY, 10016
New York, NY, 10016